Michelle A.T. Hildebrandt

Identification of genes associated with testicular germ cell tumor susceptibility through a transcriptome-wide association study

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

Identification of novel genetic loci for risk of multiple myeloma by functional annotation

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6

Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?

A pleiotropic variant in <scp><i>DNAJB4</i></scp> is associated with multiple myeloma risk

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients

Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance

XPAT: a toolkit to conduct cross-platform association studies with heterogeneous sequencing datasets

Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer

Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention